Assembly Biosciences, INC

Assembly Biosciences stockholders approved key equity incentive plan amendments and re-elected the board of directors.

Assembly Biosciences announced the pricing of an underwritten offering of common stock and pre-funded warrants, raising approximately $100 million before expenses.

Assembly Biosciences is expanding the clinical development of its oral entry inhibitor, ABI-6250, into PBC and PSC liver diseases.

Assembly Biosciences approved a 2026 cash bonus plan and raised CEO Jason Okazaki’s target bonus to 65% of base salary.

Assembly Biosciences reported strong year-end 2025 financial results, highlighted by a successful licensing deal with Gilead for its herpes program and a significant increase in cash reserves.

Assembly Biosciences reports positive interim Phase 1b results for ABI-1179 and ABI-5366, showing significant reductions in viral shedding and genital lesions for recurrent genital herpes.

Assembly Biosciences reports Q1 2026 financial results, highlighting progress in its viral disease pipeline and ongoing collaboration with Gilead Sciences.

Assembly Biosciences reported increased collaboration revenue and positive clinical trial data for its HSV programs, extending its cash runway into late 2027.

Assembly Biosciences reported continued losses and substantial doubt about its ability to continue as a going concern, despite advancing multiple clinical-stage antiviral programs and increasing collaboration revenue.

Assembly Biosciences reports a net loss of $8.8 million for Q1 2025, alongside progress in its clinical programs and collaboration with Gilead Sciences.

Assembly Biosciences reported its third quarter 2024 financial results, highlighting progress in its clinical programs and ongoing collaboration with Gilead Sciences.

Assembly Biosciences reported its second quarter 2024 financial results, highlighting progress in its clinical programs and ongoing collaboration with Gilead Sciences.

Assembly Biosciences reports positive clinical data for multiple programs and Gilead exercises its option to license the HPI program for recurrent genital herpes, significantly boosting revenue and liquidity.

Assembly Biosciences highlights advancements in its pipeline of viral disease therapeutics, including recurrent genital herpes, hepatitis delta virus, and hepatitis B virus, in its 2024 10-K filing.

Assembly Biosciences' 10-K filing details the company's capital structure, stock information, and regulatory environment, highlighting its focus on developing therapeutics for viral diseases.

Jeanette M. Bjorkquist, an officer at Assembly Biosciences, Inc., sold 29 shares of common stock to cover tax withholding obligations upon the vesting of restricted stock units.

Chief Medical Officer Anuj Gaggar acquired 14,000 restricted stock units following stockholder approval of an equity plan amendment.

Chief Manufacturing Officer Nicole S. White received 14,000 restricted stock units following shareholder approval of the 2018 Stock Incentive Plan amendment.

ASSEMBLY BIOSCIENCES, INC. Director Susan Mahony was granted 8,000 stock options with an exercise price of $24.11, aligning her interests with shareholders.

Assembly Biosciences director Lisa Johnson-Pratt was granted 8,000 stock options as part of a standard equity compensation plan.

Assembly Biosciences director Michael Houghton was granted 8,000 stock options as part of standard equity compensation.

Assembly Biosciences, Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for June 4, 2026, to elect directors and vote on key corporate proposals.

Assembly Biosciences has scheduled its 2025 Annual Meeting for June 5, 2025, and is seeking stockholder votes on director elections, executive compensation, auditor ratification, and amendments to stock incentive and purchase plans.

Assembly Biosciences is asking stockholders to approve amendments to its stock incentive and employee stock purchase plans at the 2025 Annual Meeting to increase the number of shares available for issuance.

Assembly Biosciences has scheduled its 2024 Annual Meeting of Stockholders for May 29, 2024, and is seeking votes on director elections, executive compensation, auditor ratification, and stock plan amendments.

Assembly Biosciences is asking stockholders to vote on proposals to amend its stock incentive and employee stock purchase plans at the upcoming annual meeting.

Gilead Sciences has increased its beneficial ownership in Assembly Biosciences to 25.1% following a recent public offering.

Gilead Sciences, Inc. increased its beneficial ownership in Assembly Biosciences, Inc. to 29% through a $45 million investment in common stock and warrants.

Farallon Capital Management and affiliated entities report beneficial ownership of 1,604,590 shares, representing 8.1% of Assembly Biosciences' common stock.

Paradigm BioCapital entities and Senai Asefaw, M.D. have jointly filed a Schedule 13G, reporting beneficial ownership of 5.4% of Assembly Biosciences, Inc. common stock as of May 4, 2026.

Farallon Capital Management and its affiliates updated their beneficial ownership in Assembly Biosciences, Inc., reporting a collective 7.8% stake and disclosing recent management changes within their own firm.

Janus Henderson Group plc has reported a beneficial ownership of 8.2% in Assembly Biosciences, Inc., holding 1,341,508 common shares.

RA Capital Management and its affiliates have disclosed a 9.5% beneficial ownership stake in Assembly Biosciences, Inc., including common stock and warrants.

Alexander Schornstein's beneficial ownership in Assembly Biosciences, Inc. has decreased to 3.49%, no longer requiring Schedule 13G filings.